Degarelix in the Treatment of Endometriosis Recurrence

• Status: Completed
• Trial end date: 2016-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The long acting GnRH antagonist degarelix will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
• Treatments: Goserelin; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• women affected by endometriosis showing recurrence of pain symptoms

• previous surgery for endometriosis

Exclusion Criteria:

• presence of other systemic diseases